We can’t show the full text here under this license. Use the link below to read it at the source.
Exposure–response analyses of liraglutide 3.0 mg for weight management
How different levels of liraglutide 3.0 mg relate to weight loss
AI simplified
Abstract
Weight loss increased with greater exposure to liraglutide 3.0 mg.
- The relationship between drug exposure and weight loss was evident, leveling off at higher doses for most individuals.
- Men did not exhibit a full plateau in weight loss response at the highest exposures.
- In individuals with overweight or obesity and type 2 diabetes, a clear relationship was observed between liraglutide exposure and reduction in glycated hemoglobin (HbA1c).
- HbA1c reduction increased with higher plasma liraglutide concentrations, plateauing around 21 nM, but did not fully plateau for those with baseline HbA1c levels above 8.5%.
- No significant exposure-response relationship was found for safety outcomes, aside from gastrointestinal adverse events.
AI simplified
Key numbers
8.1 kg
Weight Loss in 10% Lightest Women
Mean weight loss for the lightest women subgroup at maximum exposure.
21 nM
HbA1c Reduction Plateau
Plasma liraglutide concentration associated with maximum HbA1c reduction.
11.4 kg
Weight Loss in 10% Heaviest Men
Mean weight loss for the heaviest men subgroup at lowest exposure.